Adetunji T. Toriola, M.D., Ph.D.

Associate Professor
Surgery
Public Health Sciences

Cancer Biology Program
Human and Statistical Genetics Program
Immunology Program
Molecular Genetics and Genomics Program

  • 314-286-2668

  • a.toriola@wustl.edu

  • https://surgery.wustl.edu/people/adetunji-toriola/

  • Biomarkers, inflammation, metabolic imbalance, mammographic density, breast cancer, colorectal cancer, prevention,

  • Associations of metabolic imbalance, inflamation with cancer etiology and survival

Research Abstract:

Dr. Toriola’s research focuses on characterizing the molecular basis, and determinants of mammographic breast density and breast cancer in order to identify those that can be targeted in breast cancer prevention, especially in premenopausal women. He is the Principal Investigator on 2 R01s (R37CA23560, R01CA246592) in this research area. One of these is a phase II clinical trial investigating the effect of RANKL inhibition on mammographic breast density and breast tissue/blood markers in premenopausal women with dense breasts (R37CA235602: https://clinicaltrials.gov/ct2/show/NCT04067726). The second study uses state of the art metabolomics platforms to interrogate the metabolite profiles of mammographic breast density in premenopausal women (R01CA246592).

In addition, he performs molecular epidemiologic studies on colorectal and pancreatic cancers, evaluating the utility of biomarkers to investigate the associations of energetics, and inflammation with risk/mortality. He is MPI on the ColoCare Study (U01CA206110), a large multicenter cohort of colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes.

Selected Publications:

Toriola AT, Appleton CM, Zong X, Luo J, Weilbaecher K, Tamimi RM, Colditz GA. Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women. Cancer Prev Res (Phila). 2018 Dec;11(12):789-796. doi:
10.1158/1940-6207.CAPR-18-0199. Epub 2018 Oct 23.
PMID: 30352839.

Ulrich CM, Gigic B, Böhm J, Ose J, Viskochil R, Schneider M, Colditz GA, Figueiredo JC, Grady WM, Li CI, Shibata D, Siegel EM, Toriola AT, Ulrich A. The ColoCare Study - A paradigm of transdisciplinary science in colorectal cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2018 Dec 6. pii: cebp.0773.2018. doi: 10.1158/1055-9965.EPI-18-0773. PMID: 30523039

Alimujiang A, Imm KR, Appleton CM, Colditz GA, Berkey CS, Toriola AT. Adiposity at Age 10 and Mammographic Density among Premenopausal Women. Cancer Prev Res (Phila). 2018 May;11(5):287-294. doi: 10.1158/1940-6207.CAPR-17-0309. Epub 2018 Mar 2. PMID: 29500187.

Yang L, Toriola AT. Inflammation Modifies the Association of Obesity with Circulating 25-Hydroxyvitamin D Levels in Cancer Survivors. Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S58-S65. doi: 10.1002/oby.22011. PMID: 29086515. PMCID: PMC5679285.

Toriola AT, Ziegler M, Li Y, Pollak M, Stolzenberg-Solomon R. Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. Ann Surg Oncol. 2017 Oct;24(11):3212-3219. doi: 10.1245/s10434-017-5988-y. PMID: 28681154.

Toriola AT, Dang HA, Hagermann IS, Appleton CM, Colditz GA, Luo J, Maher CA. Increased breast tissue receptor activator of nuclear factor- kB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. Oncotarget. 2017 May 17;8(43):73787-73792. doi: 10.18632/oncotarget.17909. eCollection 2017 Sep 26. PMID: 29088745. PMCID: PMC5650300.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso HÅ, Tanner M, Kallio R, Joensuu H, Korpela J, Toriola AT, Hallmans G, Grankvist K, Zeleniuch-Jacquotte A, Toniolo P, Lundin E, Surcel HM. Human chorionic gonadotropin does not correlate with risk for maternal breast cancer: results from the Finnish maternity cohort. Cancer Res. 2017;77(1):134-141. PMID: 27784743PMCID: PMC5270509.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan D. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. PMID: 27055731. PMCID: PMC5407285.

Ulrich CM, *Rankin C, *Toriola AT, Makar KW, Altug-Teber Ö, Benedetti JK, Holmes RS, Smalley SR, Blanke DS, Lenz H-J. Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (INT-0144; SWOG 9304). Cancer 2014: 1;120(21):3329-37. PMID: 25041994 *Equal contribution. PMID: 25041994. PMCID: PMC4259283.

Toriola AT, Stolzenberg-Solomon R, Dalidowitz L, Linehan D, Colditz G. Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer 2014:111(1): 181-5. PMID: 24786605 PMCID: PMC4090724.

Toriola AT, Cheng T-YD, Neuhouser ML, Wener MH, Zheng Y, Brown E, Miller JW, Song X, Beresford SAA, Gunter MJ, Caudill MA, Ulrich CM. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 2013:132(11):2648-59. PMID: 23161620. PMCID: PMC3609926.

Last Updated: 1/24/2020 10:27:33 AM

Back To Top

Follow us: